Monoclonal Antibody Partnering Terms and Agreements 2018 Global Industry Key Players – Market Analysis and Forecast

Summary:
Wiseguyreports.Com added “Global Monoclonal Antibody Partnering Terms and Agreements 2012-2018: Deal trends, players and financials” To Its Research Database.
Scope of Report:
The Global Monoclonal antibody Partnering Terms and Agreements 2012 to 2018: Deal trends, players, financials and forecasts report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2012, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.
Key benefits
Global Monoclonal antibody Partnering Terms and Agreements 2012 to 2018 provides the reader with the following key benefits:
In-depth understanding of monoclonal antibodies deal trends since 2012
Access to headline, upfront, milestone and royalty data
Access to the structure of monoclonal antibodies agreements with numerous real life case studies
Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world’s biopharma companies
Identify the leading monoclonal antibody partnering companies
Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Monoclonal antibody Partnering Terms and Agreements 2012 to 2018 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.
Global Monoclonal antibody Partnering Terms and Agreements 2012 to 2018 includes:
  • Trends in monoclonal antibodies dealmaking in the biopharma industry since 2012
  • Analysis of monoclonal antibodies deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 700 monoclonal antibodies deal records
  • The leading monoclonal antibodies deals by value since 2012
  • Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2012
In Global Monoclonal antibody Partnering Terms and Agreements 2012 to 2018, the available deals are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Monoclonal antibodies type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Major Key Points in Table of Content:
Chapter 1 – Introduction
Chapter 2 – Trends in monoclonal antibody dealmaking
Chapter 3 – Leading monoclonal antibody deals
Chapter 4 – Most active monoclonal antibody dealmakers
Chapter 5 – Monoclonal antibody contracts dealmaking directory
Chapter 6 – Monoclonal antibody dealmaking by technology type
Chapter 7 – Partnering resource center

Continuous…

Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Comments

Popular posts from this blog

Telecoms, Mobile and Broadband 2019-2023 Laos Market Survey Industry Key Players – Lao Telecom, Thaicom, ETL, Unitel, Lao Asia Telecom, Star Telecom, Viettel

Report on Angola Telecoms, Mobile and Broadband Market Status, Market Size by Players, Regions, Type, Application and Forecast to 2021

Global Motorcycle Accessories Market by Type, by Region, by Drivers, by Competition, by Major Manufacturers, Opportunities and Forecast to 2019-2025